PLANTATION, Fla.--(BUSINESS WIRE)--Accu-Break Pharmaceuticals, Inc. (“ABP”), a company with a suite of pharmaceutical tablet technologies for creating divisible dosage forms (the “Accu-Break™ Technologies”) and Midas Pharma GmbH (“Midas”), an independent marketing and distribution company, which supports clients and manufacturing partners regarding all questions concerning Active Pharmaceutical Ingredients, Biosimilars, Custom Synthesis, Contract Manufacture, International Licensing and Pharmaceutical Dossiers, announced today the signing of a cooperation agreement.
